These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

455 related articles for article (PubMed ID: 19486092)

  • 1. Positron-emission tomography/computed tomography (PET/CT) in the initial staging of primary rectal cancer.
    Eglinton T; Luck A; Bartholomeusz D; Varghese R; Lawrence M
    Colorectal Dis; 2010 Jul; 12(7):667-73. PubMed ID: 19486092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer.
    Davey K; Heriot AG; Mackay J; Drummond E; Hogg A; Ngan S; Milner AD; Hicks RJ
    Dis Colon Rectum; 2008 Jul; 51(7):997-1003. PubMed ID: 18461399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer.
    Gearhart SL; Frassica D; Rosen R; Choti M; Schulick R; Wahl R
    Ann Surg Oncol; 2006 Mar; 13(3):397-404. PubMed ID: 16485158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
    Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
    Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the primary staging of rectal cancer.
    Ozis SE; Soydal C; Akyol C; Can N; Kucuk ON; Yagcı C; Erkek AB; Kuzu MA
    World J Surg Oncol; 2014 Feb; 12():26. PubMed ID: 24484935
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Contrast-enhanced [(18)F]fluorodeoxyglucose-positron emission tomography/computed tomography for staging and radiotherapy planning in patients with anal cancer.
    Bannas P; Weber C; Adam G; Frenzel T; Derlin T; Mester J; Klutmann S
    Int J Radiat Oncol Biol Phys; 2011 Oct; 81(2):445-51. PubMed ID: 20832181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET/MRI and PET/CT hybrid imaging of rectal cancer - description and initial observations from the RECTOPET (REctal Cancer trial on PET/MRI/CT) study.
    Rutegård MK; Båtsman M; Axelsson J; Brynolfsson P; Brännström F; Rutegård J; Ljuslinder I; Blomqvist L; Palmqvist R; Rutegård M; Riklund K
    Cancer Imaging; 2019 Jul; 19(1):52. PubMed ID: 31337428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial M Staging of Rectal Cancer: FDG PET/MRI with a Hepatocyte-specific Contrast Agent versus Contrast-enhanced CT.
    Yoon JH; Lee JM; Chang W; Kang HJ; Bandos A; Lim HJ; Kang SY; Kang KW; Ryoo SB; Jeong SY; Park KJ
    Radiology; 2020 Feb; 294(2):310-319. PubMed ID: 31793850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
    Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
    Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison between conventional imaging (abdominal-pelvic computed tomography and bone scan) and [(18)F]choline positron emission tomography/computed tomography imaging for the initial staging of patients with intermediate- tohigh-risk prostate cancer: A retrospective analysis.
    Evangelista L; Cimitan M; Zattoni F; Guttilla A; Zattoni F; Saladini G
    Scand J Urol; 2015; 49(5):345-53. PubMed ID: 25649494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
    Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
    Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of dual-time combined 18-fluorodeoxyglucose positron emission tomography and computed tomography in the staging and restaging workup of locally advanced rectal cancer, treated with preoperative chemoradiation therapy and radical surgery.
    Capirci C; Rubello D; Pasini F; Galeotti F; Bianchini E; Del Favero G; Panzavolta R; Crepaldi G; Rampin L; Facci E; Gava M; Banti E; Marano G
    Int J Radiat Oncol Biol Phys; 2009 Aug; 74(5):1461-9. PubMed ID: 19419820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
    Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
    J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.
    You JJ; Wong RK; Darling G; Gulenchyn K; Urbain JL; Evans WK
    J Thorac Oncol; 2013 Dec; 8(12):1563-9. PubMed ID: 24389439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma.
    Wilcox BE; Subramaniam RM; Peller PJ; Aughenbaugh GL; Nichols Iii FC; Aubry MC; Jett JR
    Clin Lung Cancer; 2009 Jul; 10(4):244-8. PubMed ID: 19632941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Additional benefit of ¹⁸F-fluorodeoxyglucose integrated positron emission tomography/computed tomography in the staging of oesophageal cancer.
    Gillies RS; Middleton MR; Maynard ND; Bradley KM; Gleeson FV
    Eur Radiol; 2011 Feb; 21(2):274-80. PubMed ID: 20821013
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of incidental findings on integrated 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in patients with gastric cancer.
    Tae CH; Lee JH; Choi JY; Min BH; Rhee PL; Kim JJ
    Asia Pac J Clin Oncol; 2015 Mar; 11(1):34-40. PubMed ID: 25560093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of magnetic resonance imaging-fluorodeoxy- glucose positron emission tomography fusion with pathological staging in rectal cancer.
    Kam MH; Wong DC; Siu S; Stevenson AR; Lai J; Phillips GE
    Br J Surg; 2010 Feb; 97(2):266-8. PubMed ID: 20035542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures.
    Fuster D; Duch J; Paredes P; Velasco M; Muñoz M; Santamaría G; Fontanillas M; Pons F
    J Clin Oncol; 2008 Oct; 26(29):4746-51. PubMed ID: 18695254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.